SI2258711T1 - Nove oblike 5-azacitidina - Google Patents

Nove oblike 5-azacitidina

Info

Publication number
SI2258711T1
SI2258711T1 SI200432388T SI200432388T SI2258711T1 SI 2258711 T1 SI2258711 T1 SI 2258711T1 SI 200432388 T SI200432388 T SI 200432388T SI 200432388 T SI200432388 T SI 200432388T SI 2258711 T1 SI2258711 T1 SI 2258711T1
Authority
SI
Slovenia
Prior art keywords
azacytidine
new forms
new
forms
Prior art date
Application number
SI200432388T
Other languages
English (en)
Inventor
Dumitru Ionescu
Peter Blumbergs
Lee Alani Selvey
Original Assignee
Celgene International Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2258711(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene International Sarl filed Critical Celgene International Sarl
Publication of SI2258711T1 publication Critical patent/SI2258711T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200432388T 2003-03-17 2004-03-16 Nove oblike 5-azacitidina SI2258711T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/390,578 US6887855B2 (en) 2003-03-17 2003-03-17 Forms of 5-azacytidine
EP10179540.9A EP2258711B9 (en) 2003-03-17 2004-03-16 New forms of 5-azacytidine

Publications (1)

Publication Number Publication Date
SI2258711T1 true SI2258711T1 (sl) 2017-08-31

Family

ID=32987557

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200432342A SI1610784T1 (sl) 2003-03-17 2004-03-16 Oblike 5-azacitidina
SI200432388T SI2258711T1 (sl) 2003-03-17 2004-03-16 Nove oblike 5-azacitidina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI200432342A SI1610784T1 (sl) 2003-03-17 2004-03-16 Oblike 5-azacitidina

Country Status (11)

Country Link
US (7) US6887855B2 (sl)
EP (5) EP2270022B1 (sl)
CY (2) CY1117990T1 (sl)
DK (2) DK1610784T3 (sl)
ES (2) ES2592287T3 (sl)
HU (2) HUE030717T2 (sl)
LT (1) LT1610784T (sl)
PL (2) PL2258711T3 (sl)
PT (2) PT1610784T (sl)
SI (2) SI1610784T1 (sl)
WO (1) WO2004082619A2 (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
EP2644614A3 (en) 2007-01-11 2014-02-26 IVAX Pharmaceuticals s.r.o. Solid state forms of 5-azacytidine and processes for preparation thereof
WO2009016617A2 (en) * 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
RU2488591C2 (ru) * 2007-09-26 2013-07-27 Маунт Синай Скул Оф Медсин Аналоги азацитидина и их применение
JP2011505336A (ja) * 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
WO2009139888A1 (en) * 2008-05-15 2009-11-19 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
AR073003A1 (es) * 2008-08-08 2010-10-06 Scinopharm Taiwan Ltd Proceso para preparar 5-azacitosina nucleosidos y sus derivados
EP2410987B1 (en) 2009-03-23 2018-05-16 Ambit Biosciences Corporation Methods of treatment using combination therapy
AR076418A1 (es) * 2009-04-27 2011-06-08 Reddys Lab Inc Dr Preparacion de decitabina
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
ATE534721T1 (de) * 2009-09-14 2011-12-15 Procter & Gamble Reinigungsmittelzusammensetzung
EP2521913A4 (en) * 2010-01-08 2013-05-15 Agency Science Tech & Res METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CN103338753A (zh) * 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
MX2013010945A (es) * 2011-03-31 2014-03-12 Celgene Internat Sarl Sintesis de 5 - azacitidina.
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
EP2758067A1 (en) 2011-09-23 2014-07-30 Celgene Corporation Romidepsin and 5 - azacitidine for use in treating lymphoma
KR20140069271A (ko) 2011-09-26 2014-06-09 셀진 코포레이션 화학요법 내성 암에 대한 병용 요법
UA114414C2 (uk) 2011-11-03 2017-06-12 Мілленніум Фармасьютікалз, Інк. Введення інгібітору ферменту, що активує nedd8, і гіпометилуючого засобу
WO2014076616A2 (en) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine
US9765108B2 (en) 2012-11-19 2017-09-19 Shilpa Medicare Limited Formulation of 5-azacytidine
US9968627B2 (en) 2013-03-26 2018-05-15 Celgene Corporation Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
CN103450303A (zh) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
SI3182996T1 (sl) 2014-08-22 2023-04-28 Celgene Corporation Postopki zdravljenja multiplega mieloma z imunomodulatornimi spojinami v kombinaciji s protitelesi
US20160095925A1 (en) * 2014-10-01 2016-04-07 Cadila Healthcare Limited Stable formulation of azacitidine or salts thereof and their process for preparation
GB2542881B (en) * 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
NZ741433A (en) 2015-10-15 2024-07-26 Celgene Corp Combination therapy for treating malignancies
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
WO2019025256A1 (en) 2017-08-01 2019-02-07 Bayer Aktiengesellschaft COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS
CN107827944B (zh) * 2017-11-02 2020-11-24 北京满格医药科技有限公司 一种阿扎胞苷单晶的制备方法
CN109988207B (zh) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 阿扎胞苷晶型的制备方法
CA3103436A1 (en) 2018-06-11 2019-12-19 The Regents Of The University Of California Demethylation to treat eye disease
CN110642901A (zh) * 2019-11-11 2020-01-03 扬子江药业集团有限公司 阿扎胞苷甲醇化物及其制备方法和药物组合物、用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (sl) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
TW513409B (en) 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
ES2195970T3 (es) 1996-10-16 2003-12-16 Ribapharm Inc L-ribavirina y usos de la misma.
WO2000075143A1 (fr) 1999-06-03 2000-12-14 Eisai Co., Ltd. Cristaux de derives de carbapenem et preparations pharmaceutiques pour injection
ATE312823T1 (de) 1999-07-09 2005-12-15 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
JP4870320B2 (ja) 2000-09-07 2012-02-08 株式会社カネカ ヒドロキシカルボン酸の結晶化法
ATE383355T1 (de) * 2001-03-01 2008-01-15 Abbott Lab Polymorph und andere kristallinische formen von zusammen-ftc
CA2499036A1 (en) * 2002-09-24 2004-04-08 Koronis Pharmaceuticals, Incorporated 1,3,5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
CA2503150A1 (en) 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
US7132552B2 (en) 2003-02-03 2006-11-07 Teva Pharmaceutical Industries, Ltd. Process for producing levetiracetam
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
EP2644614A3 (en) 2007-01-11 2014-02-26 IVAX Pharmaceuticals s.r.o. Solid state forms of 5-azacytidine and processes for preparation thereof
US20080182806A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
WO2009016617A2 (en) 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JP2011505336A (ja) 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
WO2009139888A1 (en) 2008-05-15 2009-11-19 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
US20100035354A1 (en) 2008-08-06 2010-02-11 Ettore Bigatti Process for preparing azacytidine intermediate
AR073003A1 (es) 2008-08-08 2010-10-06 Scinopharm Taiwan Ltd Proceso para preparar 5-azacitosina nucleosidos y sus derivados
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina

Also Published As

Publication number Publication date
EP2258710A1 (en) 2010-12-08
HUE033508T2 (en) 2017-12-28
EP2258711A2 (en) 2010-12-08
EP2258711A3 (en) 2011-03-30
EP2270023A1 (en) 2011-01-05
US7772199B2 (en) 2010-08-10
PL2258711T3 (pl) 2017-08-31
EP1610784B1 (en) 2016-07-06
US20060247189A1 (en) 2006-11-02
US20130059809A1 (en) 2013-03-07
US20140107058A1 (en) 2014-04-17
US8614313B2 (en) 2013-12-24
US7078518B2 (en) 2006-07-18
US20130059810A1 (en) 2013-03-07
US8513406B2 (en) 2013-08-20
EP1610784A4 (en) 2007-11-07
PT1610784T (pt) 2016-09-23
EP2270022B1 (en) 2016-06-29
EP2270022A1 (en) 2011-01-05
WO2004082619A2 (en) 2004-09-30
PT2258711T (pt) 2017-03-30
PL1610784T3 (pl) 2017-02-28
EP1610784A2 (en) 2006-01-04
US6887855B2 (en) 2005-05-03
CY1117990T1 (el) 2017-05-17
US20100298253A1 (en) 2010-11-25
US9192620B2 (en) 2015-11-24
EP2270023B1 (en) 2016-06-15
WO2004082619A3 (en) 2005-05-26
ES2621531T3 (es) 2017-07-04
DK2258711T3 (en) 2017-04-24
DK1610784T3 (en) 2016-09-12
EP2258711B1 (en) 2017-01-18
EP2258711B9 (en) 2017-12-27
EP2258710B1 (en) 2016-10-19
HUE030717T2 (en) 2017-05-29
SI1610784T1 (sl) 2017-01-31
CY1118805T1 (el) 2018-01-10
US20040186065A1 (en) 2004-09-23
LT1610784T (lt) 2016-10-25
US20050137150A1 (en) 2005-06-23
US8779117B2 (en) 2014-07-15
ES2592287T3 (es) 2016-11-29

Similar Documents

Publication Publication Date Title
SI2258711T1 (sl) Nove oblike 5-azacitidina
ZA200605348B (en) Solid forms of anti-EGFR-antibodies
GB0325192D0 (en) Method of use
HK1093483A1 (en) Polymorphic form of n-
EP1745573A4 (en) PROCESS FOR PREPARING 2-DEOXY-BETA-L-NUCLEOSIDES
AU2003236991A8 (en) Representations of processes
ZA200407609B (en) Use of vitamin d compounds
GB0324147D0 (en) Functionilisation of particles
AU2003298725A8 (en) Preparation of metallotexaphyrins
PL377902A1 (pl) Nowe zastosowanie kompleksu fosfor-azot-metal
TW553243U (en) Structure of clotheshanger
TW582219U (en) Improved structure of flabellum
PL356853A1 (en) Application of bacteriphages
IL165356A0 (en) Preparation of 4-haloalkylkylnicotinamides
TW515461U (en) Improved structure of squat nightstool
SI1537210T1 (sl) Lazna oligonukleotidna inhibicija ekspresije CD40
TW571665U (en) Improved structure of pensile case
TW587476U (en) Improved structure of spinning-top
TW557718U (en) Structure of brush
TW567775U (en) Structure of hairtie
GB0314360D0 (en) Prevention of uveitis
TW533774U (en) Structure improvement of flyswatter
TW539272U (en) Improved structure of extension line
TW554790U (en) Structure of screwdriver
TW573602U (en) Avstract of the disclosrte